Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE)
- 1 September 2000
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 6 (3), 264-271
- https://doi.org/10.1054/jcaf.2000.9675
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Can physicians always explain the results of clinical trials? a case study of amlodipine in heart failureThe American Journal of Cardiology, 1999
- Congestive Heart Failure in the CommunityCirculation, 1998
- Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2Journal of the American College of Cardiology, 1998
- Heart failure in the communityProgress in Cardiovascular Diseases, 1998
- Run-in Periods in Randomized TrialsPublished by American Medical Association (AMA) ,1998
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Conclusions. 1: The relationship between clinical trials and clinical practice: The risks of underestimating its complexityStatistics in Medicine, 1994
- Studies of left ventricular dysfunction (SOLVD) registry: Rationale, design, methods and description of baseline characteristicsThe American Journal of Cardiology, 1992
- Congestive heart failure symptoms in patients with preserved left ventricular systolic function: Analysis of the CASS registryJournal of the American College of Cardiology, 1991
- Acute Myocardial Infarction: One Year Follow‐up of 1138 Cases from the Perth Community Coronary RegisterAustralian and New Zealand Journal of Medicine, 1976